Viant Bio, Inc. (NASDAQ:VYNT – Get a rating) benefited from a sharp fall in short-term interest rates during the month of June. As of June 30, there was short interest totaling 224,000 shares, a decrease of 37.3% from the total of 357,200 shares as of June 15. Based on an average daily volume of 106,900 shares, the day-to-cover ratio is currently 2.1 days. Approximately 0.9% of the company’s shares are sold short.

Vyant Bio price performance

Shares of Stock Viant Bio opened at $0.87 on Friday. The company has a debt ratio of 0.01, a quick ratio of 2.67 and a current ratio of 2.74. Vyant Bio has a 12 month minimum of $0.60 and a 12 month maximum of $3.30. The company has a 50-day moving average of $0.76 and a 200-day moving average of $1.01.

Bio light (NASDAQ:VYNT – Get a rating) last released its quarterly results on Monday, May 16. The company reported ($0.15) EPS for the quarter, beating analyst consensus estimates of ($0.16) by $0.01. The company posted revenue of $0.30 million in the quarter, compared to $0.30 million expected by analysts. Equity analysts expect Vyant Bio to post -0.56 earnings per share for the current fiscal year.

A Wall Street analyst gives his opinion

Separately, HC Wainwright reduced its price target on Vyant Bio to $3.00 and set a “buy” rating for the company in a research report on Tuesday, May 17.

Institutional entries and exits

A hedge fund recently increased its stake in Vyant Bio stock. US Bancorp DE increased its stake in Vyant Bio, Inc. (NASDAQ:VYNT – Get a rating) by 3,001.6% in the first quarter, according to its most recent Form 13F filing with the SEC. The fund held 24,813 shares of the company after purchasing an additional 24,013 shares during the period. US Bancorp DE owned approximately 0.08% of Vyant Bio worth $35,000 at the end of the most recent reporting period. 8.71% of the shares are held by institutional investors and hedge funds.

Viant Bio Company Profile

(Get a rating)

Vyant Bio, Inc, a biotechnology company, discovers drugs for complex neurodevelopmental and neurodegenerative disorders. The Company’s central nervous system (CNS) drug discovery platform combines human-derived organoid models of brain disease, scale biology and machine learning. He focuses on identifying repurposed and novel small molecule clinical candidates for rare genetic CNS disorders, including Rett syndrome (Rett), CDKL5 deficiency disorders (CDD), and familial Parkinson’s disease (PD) .

Further reading

Get news and reviews for Vyant Bio Daily – Enter your email address below to receive a concise daily summary of breaking news and analyst ratings for Vyant Bio and related companies with MarketBeat.com’s FREE daily newsletter.